Oncobiologics Inc.
News
Private equity firms are Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners and were rewarded after market cap rose by US$30m last week
Simply Wall St Key Insights Outlook Therapeutics' significant private equity firms ownership suggests that the key decisions are...\n more…
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Brokerages
Ticker Report Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven analysts that are covering the firm, Marketbeat.com reports...\n more…
Outlook Therapeutics (NASDAQ:OTLK) PT Lowered to $33.00
Ticker Report Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) had its target price cut by research analysts at Ascendiant Capital Markets from $35.00 to $33.00 in a research report issued to clients and...\n more…
Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
Globe Newswire Topline results from NORSE EIGHT expected in Q4 CY2024 ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved...\n more…
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles
Seeking Alpha - Long Ideas Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles...\n more…
Outlook Therapeutics, Inc. to Post FY2024 Earnings of ($3.90) Per Share, Brookline Capital Management Forecasts (NASDAQ:OTLK)
Ticker Report Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Stock analysts at Brookline Capital Management reduced their FY2024 earnings per share estimates for Outlook Therapeutics in a research report...\n more…